Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study
Authors:
- Isamu OkamotoIOIsamu Okamoto
- Hiroshige YoshiokaHYHiroshige Yoshioka
- Satoshi MoritaSMSatoshi Morita
- Masahiko AndoMAMasahiko Ando
- Koji TakedaKTKoji Takeda
- Takashi SetoTSTakashi Seto
- Nobuyuki YamamotoNYNobuyuki Yamamoto
- Hideo SakaHSHideo Saka
- Kazuhiro AsamiKAKazuhiro Asami
- Tomonori HirashimaTHTomonori Hirashima
- Shinzoh KudohSKShinzoh Kudoh
- Miyako SatouchiMSMiyako Satouchi
- 20 December 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (36) , 5240-5246
Abstract
Purpose: The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods: A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m2 twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m2) on day 1 every 21 days. Results: At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2% CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3% and 55.5%, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm. Conclusion: Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.Keywords
This publication has 13 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancerEuropean Journal of Cancer, 2009
- S-1: A New Oral Fluoropyrimidine in the Treatment of Patients with Advanced Non–Small-Cell Lung CancerClinical Lung Cancer, 2009
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLJournal of Clinical Oncology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals of Oncology, 2006
- Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancerBritish Journal of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995